Alzheimer’s Drug May Benefit Some Patients, New Data Showsnews2022-11-30T00:50:06+00:00November 30th, 2022|The New York Times|
Alzheimer’s Drug Slows Cognitive Decline in Key Studynews2022-09-28T13:42:59+00:00September 28th, 2022|The New York Times|
Biogen Agrees to Pay $900 Million to Settle Lawsuit Over Kickbacksnews2022-09-27T00:35:45+00:00September 27th, 2022|The New York Times|
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelmnews2022-05-03T18:00:36+00:00May 3rd, 2022|The New York Times|
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trialsnews2022-04-07T23:32:59+00:00April 7th, 2022|The New York Times|
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drugnews2022-04-06T18:43:00+00:00April 6th, 2022|The New York Times|
In India, Parents of Children with Rare Disease Plea for Help Onlinenews2022-04-06T12:29:44+00:00April 6th, 2022|The New York Times|
Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelmnews2022-01-12T01:22:10+00:00January 12th, 2022|The New York Times|
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decisionnews2021-12-31T21:39:22+00:00December 31st, 2021|The New York Times|
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstaclesnews2021-12-21T02:08:14+00:00December 21st, 2021|The New York Times|
